BNP Paribas Financial Markets
GLUE icon

BNP Paribas Financial Markets’s Monte Rosa Therapeutics GLUE Stock Holding History

BNP Paribas Financial Markets’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$328K Sell
13,568
-31,495
-70% -$595K ﹤0.01% 3991
2026
Q1 		$741K Buy
45,063
+39,369
+691% +$753K ﹤0.01% 3350
2025
Q4 		$89.3K Sell
5,694
-4,039
-41% -$54.4K ﹤0.01% 4424
2025
Q3 		$72.1K Buy
9,733
+4,565
+88% +$24.2K ﹤0.01% 4439
2025
Q2 		$23.3K Buy
5,168
+2,234
+76% +$9.96K ﹤0.01% 4536
2025
Q1 		$13.6K Sell
2,934
-3,297
-53% -$20.2K ﹤0.01% 4640
2024
Q4 		$43.2K Buy
+6,231
New +$46.8K ﹤0.01% 4480

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BNP Paribas Financial Markets's GLUE Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Monte Rosa Therapeutics (GLUE) stake by 70% in Q2 2026, selling an estimated $595K and leaving 13,568 shares worth $328K. The position accounts for ﹤0.01% of the portfolio, ranked #3991.

BNP Paribas Financial Markets first reported a position in GLUE in Q4 2024 and has held it in 7 quarters since. The position peaked at $741K in Q1 2026. 175 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • BNP Paribas Financial Markets held 13,568 shares of Monte Rosa Therapeutics worth $328K as of Q2 2026.
  • BNP Paribas Financial Markets sold 31,495 Monte Rosa Therapeutics shares in Q2 2026, an estimated $595K.
  • Monte Rosa Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3991 holding.
  • BNP Paribas Financial Markets first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Monte Rosa Therapeutics position peaked at $741K in Q1 2026.
  • 175 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.